4.3 Article

Corneal confocal microscopy as a tool for detecting diabetic polyneuropathy in a cohort with screen-detected type 2 diabetes: ADDITION-Denmark

Journal

JOURNAL OF DIABETES AND ITS COMPLICATIONS
Volume 32, Issue 12, Pages 1153-1159

Publisher

ELSEVIER SCIENCE INC
DOI: 10.1016/j.jdiacomp.2018.09.016

Keywords

Diabetes; Diabetic polyneuropathy; Corneal confocal microscopy; Diabetic complication; Toronto consensus criteria

Funding

  1. Novo Nordisk Foundation [NNF14OC0011633]
  2. National Health Services in the County of Copenhagen in Denmark
  3. Danish Council for Strategic Research
  4. Danish Research Foundation for General Practice
  5. Novo Nordisk Foundation
  6. Danish Center for Evaluation and Health Technology Assessment
  7. Danish National Board of Health
  8. Danish Medical Research Council
  9. Aarhus University Research Foundation
  10. Novo Nordisk Scandinavia AB
  11. Pfizer Denmark
  12. Danish Diabetes Academy - Novo Nordisk Foundation
  13. Novo Nordisk UK: ASTRA Denmark
  14. GlaxoSmithKline Pharma Denmark
  15. National Health Services in the County of Aarhus in Denmark
  16. National Health Services in the County of Ringkobing in Denmark
  17. National Health Services in the County of Ribe in Denmark
  18. National Health Services in the County of South Jutland in Denmark
  19. Servier Denmark A/S
  20. HemoCue Denmark A/S

Ask authors/readers for more resources

Aims: In this cross-sectional study, we explored the utility of corneal confocal microscopy (CCM) measures for detecting diabetic polyneuropathy (DPN) and their association with clinical variables, in a cohort with type 2 diabetes. Methods: CCM, nerve conduction studies, and assessment of symptoms and clinical deficits of DPN were undertaken in 144 participants with type 2 diabetes and 25 controls. DPN was defined according to the Toronto criteria for confirmed DPN. Results: Corneal nerve fiber density (CNFD) was lower both in participants with confirmed DPN (n = 27) and in participants without confirmed DPN (n = 117) compared with controls (P = 0.04 and P = 0.01, respectively). No differences were observed for CNFD (P = 0.98) between participants with and without DPN. There were no differences in CNFL and CNBD between groups (P = 0.06 and P = 0.29, respectively). CNFD was associated with age, height, total- and LDL cholesterol. Conclusions: CCM could not distinguish patients with and without neuropathy, but CNFD was lower in patients with type 2 diabetes compared to controls. Age may influence the level of CCM measures. (C) 2018 Elsevier Inc. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.3
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available